Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • ADX71149 for epilepsy
  • Dipraglurant for PD-LID, pain, SUD, NDD and stroke rehabilitation
  • GABAB PAM for substance use disorder
  • GABAB PAM for CMT1A, chronic cough and pain
  • mGlu7 NAM for PTSD
  • mGlu2 NAM for mild neurocognitive disorders
  • M4 PAM for schizophrenia & other psychosis
  • mGlu4 PAM for Parkinson’s disease
  • mGlu3 PAM for neurodegenerative disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 03.28
    2023

    Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023

  • 03.16
    2023

    Addex Announces Upcoming Conferences it will participate for H1 2023

  • 02.09
    2023

    Addex Regains Nasdaq Listing Compliance

  • 02.06
    2023

    Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1

  • 01.19
    2023

    Addex Provides Corporate Update and Financial Guidance

Contact us

If you have any questions please let me know
  • Contact form
2023 © Addex therapeutics